Solini A - Search Results

1

Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors.

Chiriacò M, Tricò D, Solini A. Chiriacò M, et al. Among authors: solini a. Curr Opin Pharmacol. 2022 Oct;66:102272. doi: 10.1016/j.coph.2022.102272. Epub 2022 Aug 11. Curr Opin Pharmacol. 2022. PMID: 35964531 Review.

2

Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.

Solini A. Solini A. Acta Diabetol. 2016 Dec;53(6):863-870. doi: 10.1007/s00592-016-0856-y. Epub 2016 Apr 1. Acta Diabetol. 2016. PMID: 27038028 Review.

3

Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.

Solini A, Rossi C, Mazzanti CM, Proietti A, Koepsell H, Ferrannini E. Solini A, et al. Diabetes Obes Metab. 2017 Sep;19(9):1289-1294. doi: 10.1111/dom.12970. Epub 2017 May 22. Diabetes Obes Metab. 2017. PMID: 28419670

4

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.

Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L, Bruno RM. Solini A, et al. Cardiovasc Diabetol. 2017 Oct 23;16(1):138. doi: 10.1186/s12933-017-0621-8. Cardiovasc Diabetol. 2017. PMID: 29061124 Free PMC article.

5

P2X receptor-ion channels in the inflammatory response in adipose tissue and pancreas-potential triggers in onset of type 2 diabetes?

Novak I, Solini A. Novak I, et al. Among authors: solini a. Curr Opin Immunol. 2018 Jun;52:1-7. doi: 10.1016/j.coi.2018.02.002. Epub 2018 Mar 6. Curr Opin Immunol. 2018. PMID: 29522971 Review.

6

Role of the P2X7 receptor in the pathogenesis of type 2 diabetes and its microvascular complications.

Solini A, Novak I. Solini A, et al. Curr Opin Pharmacol. 2019 Aug;47:75-81. doi: 10.1016/j.coph.2019.02.009. Epub 2019 Apr 5. Curr Opin Pharmacol. 2019. PMID: 30954933 Review.

7

The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature.

Solini A, Seghieri M, Giannini L, Biancalana E, Parolini F, Rossi C, Dardano A, Taddei S, Ghiadoni L, Bruno RM. Solini A, et al. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4253-4263. doi: 10.1210/jc.2019-00706. J Clin Endocrinol Metab. 2019. PMID: 31162549 Clinical Trial.

8

Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.

Spigoni V, Fantuzzi F, Carubbi C, Pozzi G, Masselli E, Gobbi G, Solini A, Bonadonna RC, Dei Cas A. Spigoni V, et al. Among authors: solini a. Cardiovasc Diabetol. 2020 Apr 7;19(1):46. doi: 10.1186/s12933-020-01016-5. Cardiovasc Diabetol. 2020. PMID: 32264868 Free PMC article.

9

Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?

Giorgino F, Vora J, Fenici P, Solini A. Giorgino F, et al. Among authors: solini a. Diabetes Obes Metab. 2020 Sep;22(9):1481-1495. doi: 10.1111/dom.14055. Epub 2020 May 7. Diabetes Obes Metab. 2020. PMID: 32285611 Free PMC article. Review.

10

Protein and amino acids in nonalcoholic fatty liver disease.

Tricò D, Biancalana E, Solini A. Tricò D, et al. Among authors: solini a. Curr Opin Clin Nutr Metab Care. 2021 Jan;24(1):96-101. doi: 10.1097/MCO.0000000000000706. Curr Opin Clin Nutr Metab Care. 2021. PMID: 33060460 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

264 results

Search Page